RegeneRx Receives Notice of Allowance on U.S. Patent for Skin Protection and Repair

RegeneRx Biopharmaceuticals, Inc.

announced today that the Company received a notice of allowance from the U.S. Patent and Trademark Office for one of the original patent applications submitted by the National Institutes of Health. The patent contains claims directed to compositions for topical administration of Thymosin beta 4 (Tβ4) to skin and to methods for improving or treating damage to skin, including from radiation or scar tissue, and to methods of regenerating or revitalizing skin tissue.